铁剂联合促红细胞生成素治疗缺铁性贫血的疗效观察

目的：探讨铁剂联合促红细胞生成素治疗缺铁性贫血的临床疗效，为临床推广做出指导。方法选择该院自2010年1月-2013年1月收治的86例缺铁性贫血的患儿为研究对象，将其完全随机分为两组，对照组患者给予蛋白琥珀酸铁口服液治疗，观察组患者则在对照组的基础上给予重组人红细胞生成素治疗，对比观察两组患儿的临床治疗效果。结果观察组治疗后血红蛋白（97.69±18.46） g/L、血清铁蛋白（17.59±3.98） g/L、以及血细胞比积（37.59±6.68）%等各项指标均优于对照组治疗后血红蛋白（81.32±16.11） g/L、血清铁蛋白（14.16±3.21） g/L、以及血细胞比积（28.35±6.03）%，差异有统计学意义（P〈0.05）。结论铁剂联合促红细胞生成素治疗缺铁性贫血的临床疗效显著，能够改善患儿的缺血症状，值得临床广泛推广。

Observation on the Effect of Iron Combined with Erythropoietin in the Treatment of Iron-deficiency Anemia

Objective To investigate the clinical effect of iron combined with erythropoietin in the treatment of iron-deficiency anemia so as to provide guidance for the clinical promotion. Methods 86 cases of children with iron-deficiency anemia admitted in our hospital from January 2010 to January 2013 were selected as the object of study, and they were randomly divided into two groups. Patients in the control group were treated with iron proteinsuccinylate oral solution, and patients in the observation group were given recombinant human erythropoietin treatment on the basis of the treatment of the control group. The clinical treatment effect of these two groups of children was observed and compared. Results After the treatment, the hemoglobin of the observation group was （97.69 ±18.46 ）g/L, serum ferritin was （17.59 ±3.98） g/L, haematocrit was （37.59 ±6.68）%, the hemoglobin of the control group was （81.32±16.11 ）g/L, serum ferritin was （14.16±3.21） g/L, haematocrit was （28.35±6.03） %, the indicators of the observa-tion group were better than those of the control group after treatment, the differences between the two groups were statistically sig-nificant （P〈0.05）. Conclusion The therapeutic effect of iron combined with erythropoietin for the treatment of iron-deficiency ane-mia is significant, which can improve the ischemic symptoms of the children, and is worthy of extensive clinical application.